Atracurium (besylate)

• UNSPSC Description:

  Atracurium (BW-33A) besylate is a potent, competitive and non-depolarizing neuromuscular blocking agent. Atracurium besylate also is an AChR receptor antagonist. Atracurium besylate induces bronchoconstriction and neuromuscular blockade. Atracurium besylate promotes astroglial differentiation[1][2][3][4][5].

• Target Antigen:

  nAChR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Atracurium-besylate.html

• Purity:

  99.14

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  O=S(C1=CC=CC=C1)([O-])=O.O=C(OCCCCCOC(CC[N+]2(C)C(CC3=CC=C(OC)C(OC)=C3)C4=C(C=C(OC)C(OC)=C4)CC2)=O)CC[N+]5(C)C(CC6=CC=C(OC)C(OC)=C6)C7=C(C=C(OC)C(OC)=C7)CC5.O=S(C8=CC=CC=C8)([O-])=O

• Molecular Weight:

  1243.48

• References & Citations:

  [1]Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61(9):723-9.|[2]Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151(5):1537-42.|[3]Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18(9):599-604.|[4]Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7(1):459-72.|[5]Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):9-14.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  64228-81-5